Suppr超能文献

用于推断肿瘤起源和治疗抗性机制的单细胞转录组分析

Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance.

作者信息

Lin Maoxuan, Sade-Feldman Moshe, Wirth Lori, Lawrence Michael S, Faden Daniel L

机构信息

Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA, 02118, USA.

Massachusetts General Hospital Cancer Center, Boston, MA, 02118, USA.

出版信息

NPJ Precis Oncol. 2022 Oct 10;6(1):71. doi: 10.1038/s41698-022-00314-3.

Abstract

Head and Neck Squamous Cell Carcinoma (HNSCC) is an aggressive epithelial cancer with poor overall response rates to checkpoint inhibitor therapy (CPI) despite CPI being the recommended treatment for recurrent or metastatic HNSCC. Mechanisms of resistance to CPI in HNSCC are poorly understood. To identify drivers of response and resistance to CPI in a unique patient who was believed to have developed three separate HNSCCs, we performed single-cell RNA-seq (scRNA-seq) profiling of two responding lesions and one progressive lesion that developed during CPI. Our results not only suggest interferon-induced APOBEC3-mediated acquired resistance as a mechanism of CPI resistance in the progressing lesion but further, that the lesion in question was actually a metastasis as opposed to a new primary tumor, highlighting the immense power of scRNA-seq as a clinical tool for inferring tumor origin and mechanisms of therapeutic resistance.

摘要

头颈部鳞状细胞癌(HNSCC)是一种侵袭性上皮癌,尽管检查点抑制剂疗法(CPI)是复发性或转移性HNSCC的推荐治疗方法,但总体缓解率仍较低。HNSCC对CPI耐药的机制尚不清楚。为了确定一名被认为发生了三种不同HNSCC的独特患者对CPI的反应和耐药驱动因素,我们对两个反应性病变和一个在CPI治疗期间出现的进展性病变进行了单细胞RNA测序(scRNA-seq)分析。我们的结果不仅表明干扰素诱导的载脂蛋白B mRNA编辑酶催化多肽样3(APOBEC3)介导的获得性耐药是进展性病变中CPI耐药的一种机制,而且进一步表明,该病变实际上是转移灶而非新发原发性肿瘤,凸显了scRNA-seq作为推断肿瘤起源和治疗耐药机制的临床工具的巨大作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb29/9548500/ade2fab81ac0/41698_2022_314_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验